HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 3, 2016, Pages 739-750

  Di Maio, V C ^a,l   Cento, V ^a,l   Di Paolo, D ^b,l   Aragri, M ^a,l   De Leonardis, F ^b,l   Tontodonati, M ^c,l   Micheli, V ^d,l   Bellocchi, M ^l   Antonucci, F P ^a,l   Bertoli, A ^a,l   Lenci, I ^b,l   Milana, M ^b,l   Gianserra, L ^e,l   Melis, M ^f,l   Di Biagio, A ^g,l   Sarrecchia, C ^b,l   Sarmati, L ^b,l   Landonio, S ^d,l   Francioso, S ^b,l   Lambiase, L ^e,l   Nicolini, L A ^g,l   Marenco, S ^h,l   Nosotti, L ^i,l   Giannelli, V ^j,l   Siciliano, M ^k,l   Romagnoli, D ^l   Pellicelli, A ^l,m   Vecchiet, J ^l,n   Magni, C F ^d,l   Babudieri, S ^f,l   Mura, M S ^f,l   Taliani, G ^j,l   Mastroianni, C ^j,l   Vespasiani Gentilucci, U ^l,o   Romano, M ^l,p   Morisco, F ^l,q   Gasbarrini, A ^k,l   Vullo, V ^l,r   Bruno, S ^l,s   Baiguera, C ^t   Pasquazzi, C ^e,l   Tisone, G ^a,l   Picciotto, A ^h,l   Andreoni, M ^b,l   Parruti, G ^c,l   Rizzardini, G ^d,l   Angelico, M ^b,l   Perno, C F ^a,b,l   Ceccherini Silberstein, F ^a,l   Mariani, R ^l   Paoloni, M ^l   Iapadre, N ^l   Grimaldi, A ^l   Menzaghi, B ^u   Quirino, T ^u   Bruzzone, B ^l   De Maria, A ^l   Viscoli, C ^l   Casinelli, K ^l   Delle Monache, M ^l   Lichtner, M ^l   Aghemo, A ^l   Cerrone, M ^l   Colombo, M ^l   D'Arminio Monforte, A ^l   Danieli, E ^l   Donato, F ^l   Gubertini, G ^l   Mancon, A ^l   Monico, S ^l   Niero, F ^l   Puoti, M ^l   Russo, M L ^l   Alfieri, R ^l   Gnocchi, M ^l   Orro, A ^l   Milanesi, L ^l   Baldelli, E ^l   Bertolotti, M ^l   Borghi, V ^l   Mussini, C ^l   Brancaccio, G ^l   Caporaso, N ^l   Gaeta, G B ^l   Lembo, V ^l   Calvaruso, V ^l   Craxi A ^l   Di Marco, V ^l   Mazzola, A ^l   Petta, S ^l   D'Amico, E ^v   Cacciatore, P ^l   Consorte, A ^l   Pace Palitti, V ^l   Pieri, A ^l   Polilli, E ^l   Antenucci, F ^l   Armenia, D ^l   Baiocchi, L ^l   Biliotti, E ^l   Biolato, M ^l   Carioti, L ^l   Cerasari, G ^l   Cerva, C ^l   Ciotti, M ^l   D'Ambrosio, C ^l   D'Ettorre, G ^l   De Sanctis, A ^l   Furlan, C ^l   Gallo, P ^l   Grieco, A ^l   Grieco, S ^l   Lattanzi, B ^l   Malagnino, V ^l   Manuelli, M ^l   Merli, M ^l   Miglioresi, L ^l   Palazzo, D ^l   Santopaolo, F ^l   Santoro, M M ^l   Sforza, D ^l   Sorbo, M C ^l   Spaziante, M ^l   Svicher, V ^l   Teti, E ^l   Mangia, A ^l   Maida, I ^l   Falconi, L ^l   Di Giammartino, D ^l   Tarquini, P ^l   more..

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c Pescara General Hospital   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF SASSARI   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k CATHOLIC UNIVERSITY   (Italy)

^l San Camillo Forlanini Hospital ^*  (Italy)

^m SAN CAMILLO FORLANINI HOSPITAL   (Italy)

ⁿ Infectious Diseases Clinic   (Italy)

^o UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^p SANDRO PERTINI HOSPITAL   (Italy)

^q UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^r SAPIENZA UNIVERSITY OF ROME   (Italy)

^s HUMANITAS UNIVERSITY   (Italy)

^t OSPEDALE NIGUARDA CA GRANDA   (Italy)

^u Hospital Niguarda Ca'Granda ^*  (Italy)

^v Section of Radiology S Massimo Hospital   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR; SIMEPREVIR; TELAPREVIR; VIRUS RNA; NS3 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENE AMPLIFICATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2A; HEPATITIS C VIRUS GENOTYPE 2C; HEPATITIS C VIRUS GENOTYPE 4D; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; MAJOR CLINICAL STUDY; MUTATION; PHYLOGENY; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIRUS RESISTANCE; CLASSIFICATION; DNA SEQUENCE; DRUG EFFECTS; EVALUATION STUDY; GENETICS; GENOTYPING TECHNIQUE; HEPACIVIRUS; ISOLATION AND PURIFICATION; PROCEDURES; RETROSPECTIVE STUDY; VIROLOGY;

DRUG RESISTANCE, VIRAL; GENOTYPE; GENOTYPING TECHNIQUES; HEPACIVIRUS; HEPATITIS C; HUMANS; MUTATION; RETROSPECTIVE STUDIES; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84960808354     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv403     Document Type: Article

References (59)

1. Messina JP, Humphreys I, Flaxman A et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87.
2. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
3. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
4. European Association for the Study of the Liver. EASL Recommendation on Treatment of Hepatitis C 2015. http://www.easl.eu/medias/cpg/HEPC-2015/Full-report.pdf.
5. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932-54.
6. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014; 146: 1176-92.
7. Ferenci P, Bernstein D, Lalezari J et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-92.
8. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
9. Kieffer TL, De MS, Bartels DJ et al. Hepatitis Cviral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevirbased therapy in clinical trials. PLoS One 2012; 7: e34372.
10. Gane EJ, Pockros P, Zeuzem S et al. Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatment-naive HCV genotype 1 infected patients. J Hepatol 2012; 56 Suppl 2: S555-6.
11. Poordad F, Agarwal K, Younes Z et al. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study. Clin Infect Dis 2015; 60: 608-10.
12. Poordad F, Hezode C, Trinh R et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-82.
13. Ceccherini SF, Di Maio VC, Aragri M et al. Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents. Hepatology 2015; doi:10.1002/hep.27895.
14. Sullivan JC, De MS, Bartels DJ et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 2013; 57: 221-9.
15. Howe AY, Long J, Nickle D et al. Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C. Antiviral Res 2015; 113: 71-8.
16. Bartels DJ, Sullivan JC, Zhang EZ et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013; 87: 1544-53.
17. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: dowe need resistance testing? Antiviral Res 2014; 105: 64-71.
18. Soriano V, Vispo E, Poveda E et al. Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother 2012; 13: 313-23.
19. Bartels DJ, Zhou Y, Zhang EZ et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198: 800-7.
20. Kuntzen T, Timm J, Berical A et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48: 1769-78.
21. Trimoulet P, Belzunce C, Faure M et al. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCVcoinfected patients. HIV Med 2011; 12: 506-9.
22. Sarrazin C, Lathouwers E, Peeters M et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res 2015; 116: 10-6.
23. Vicenti I, Rosi A, Saladini F et al. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCVgenotype 1-infected subjects in Italy. J Antimicrob Chemother 2012; 67: 984-7.
24. Simeprevir Prescribing Information. http://www.olysio.com/shared/product/olysio/prescribing-information.pdf.
25. Svarovskaia ES, ZeuzemS, Hedskog C et al. Prevalence of pretreatment NS5A and NS5B resistance-associated variants and genetic variation within HCV subtypes across different countries/Gilead-Study. In: Abstracts of the Fiftieth International Liver Congress, Vienna, 2015. Abstract P0892, p. S678. European Association for the Study of the Liver, Geneva, Switzerland
26. Karino Y, Toyota J, Ikeda K et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013; 58: 646-54.
27. Sarrazin C, Dvory-Sobol H, Svarovskaia ES et al. The prevalence and the effect of HCV NS5A resistance-associated variants in patients with compensated cirrhosis treated with ledipasvir/sofosbuvir+RBV. In: Abstracts of the Fiftieth International Liver Congress, Vienna, 2015. Abstract P0773, p. S620. European Association for the Study of the Liver, Geneva, Switzerland.
28. Reddy KR, Beavers KL, Gordon S et al. Effect of baseline factors on response to the fixed-dose combination of daclatasvir (DCV), asunaprevir (ASV) and beclabuvir (BCV) in non-cirrhotic patients with HCV genotype 1 infection. In: Abstracts of the Fiftieth International Liver Congress, Vienna, 2015. Abstract P0888, p. S676. European Association for the Study of the Liver, Geneva, Switzerland.
29. Lawitz E, Flamm S, Yang JC et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. In: Abstracts of the Fiftieth International Liver Congress, Vienna, 2015. Abstract O005, p. S192. European Association for the Study of the Liver, Geneva, Switzerland.
30. Kwo P, Gane E, Peng C et al. Efficacy and safety of grazoprevir/elbasvir +/2RBV for 12 or 16 weeks in patients with HCVg1, g4 or g6 infection who previously failed peginterferon/RBV: c-edge treatment-experienced. In: Abstracts of the Fiftieth International Liver Congress, Vienna, 2015. Abstract P0886, p. S674. European Association for the Study of the Liver, Geneva, Switzerland.
31. Lawitz E, Lalezari JP, Hassanein T et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-8.
32. Lawitz E, Sulkowski MS, Ghalib R et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-65.
33. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
34. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.
35. Lawitz E, Matusow G, DeJesus E et al. A Phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or-experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2. In: Abstracts of the Fiftieth International Liver Congress, Vienna, 2015. Abstract LP04, p. S264. European Association for the Study of the Liver, Geneva, Switzerland.
36. Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-603.
37. Muir AJ, Poordad F, Lalezari J et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis Cvirus genotype 1 infection with compensated cirrhosis. JAMA 2015; 313: 1736-44.
38. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987; 4: 406-25.
39. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980; 16: 111-20.
40. Tamura K, Peterson D, Peterson N et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011; 28: 2731-9.
41. Poveda E, Wyles DL, Mena A et al. Update on hepatitis Cvirus resistance to direct-acting antiviral agents. Antiviral Res 2014; 108: 181-91.
42. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012; 26: 487-503.
43. Lontok E, Harrington P, Howe A et al. Hepatitis C virus drug resistanceassociated substitutions: state of the art summary. Hepatology 2015; 62: 1623-32.
44. Alexopoulou A, Karayiannis P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann Gastroenterol 2015; 28: 55-65.
45. Cento V, Landonio S, De Luca F et al. A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy. Antivir Ther 2013; 18: 645-8.
46. Romagnoli D, Marrazzo A, Ballestri S et al. Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma. J Clin Virol 2015; 69: 74-7.
47. Benedet M, Adachi D, Wong A et al. The need for a sequencing-based assay to supplement the Abbott m2000 RealTime HCV Genotype II assay: a 1 year analysis. J Clin Virol 2014; 60: 301-4.
48. Chevaliez S, Bouvier-Alias M, Brillet R et al. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009; 4: e8209.
49. Larrat S, Poveda JD, Coudret C et al. Sequencing assays for failed genotyping with the Versant hepatitis C virus genotype assay (LiPA), version 2.0. J Clin Microbiol 2013; 51: 2815-21.
50. Mallory MA, Lucic DX, Sears MTet al. Evaluation of the Abbott RealTime HCV Genotype II RUO (GT II) assay with reference to 5'UTR, core and NS5B sequencing. J Clin Virol 2014; 60: 22-6.
51. Liu CH, Liang CC, Liu CJ et al. Comparison of Abbott RealTime HCV Genotype II with Versant line probe assay 2.0 for hepatitis C virus genotyping. J Clin Microbiol 2015; 53: 1754-7.
52. Wyles DL, Gutierrez JA. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. J Viral Hepat 2014; 21: 229-40.
53. Besse B, Coste-Burel M, Bourgeois N et al. Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitivemethod. J VirolMethods 2012; 185: 94-100.
54. Shindo H, Maekawa S, Komase K et al. Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients. Hepatol Int 2012; 6: 482-90.
55. Shepherd SJ, Abdelrahman T, MacLean AR et al. Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. J Clin Virol 2015; 65: 50-3.
56. Poordad F, Bronowicki JP, Gordon SC et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 608-18.
57. Cento V, Mirabelli C, Salpini R et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One 2012; 7: e39652.
58. Schinazi R, Halfon P, Marcellin P et al. HCVdirect-acting antiviral agents: the best interferon-free combinations. Liver Int 2014; 34 Suppl 1: 69-78.
59. Susser S, Vermehren J, Forestier N et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011; 52: 321-7.